Neuraminidase inhibitor susceptibility and neuraminidase enzyme kinetics of human influenza A and B viruses circulating in Thailand in 2010–2015

Nipaporn Tewawong; Bindumadhav M. Marathe; Yong Poovorawan; Sompong Vongpunsawad; Richard J. Webby; Elena A. Govorkova

doi:10.1371/journal.pone.0190877

Abstract

Amino acid substitutions within or near the active site of the viral neuraminidase (NA) may affect influenza virus fitness. In influenza A(H3N2) and B viruses circulating in Thailand between 2010 and 2015, we identified several NA substitutions that were previously reported to be associated with reduced inhibition by NA inhibitors (NAIs). To study the effect of these substitutions on the enzymatic properties of NA and on virus characteristics, we generated recombinant influenza viruses possessing either a wild type (WT) NA or an NA with a single I222V, S331G, or S331R substitution [in influenza A(H3N2) viruses] or a single D342S, A395T, A395V, or A395D NA substitution (in influenza B viruses). We generated recombinant (7:1) influenza A and B viruses on the genetic background of A/Puerto Rico/8/1934 (A/PR/8, H1N1) or B/Yamanashi/166/1998 (B/YAM) viruses, respectively. In contrast to the expected phenotypes, all the recombinant influenza A(H3N2) and B viruses carrying putative NA resistance substitutions were susceptible to NAIs. The K_m and V_max for the NAs of A/PR8-S331G and A/PR8-S331R viruses were higher than for the NA of WT virus, and the corresponding values for the B/YAM-D342S virus were lower than for the NA of WT virus. Although there was initial variation in the kinetics of influenza A and B viruses’ replication in MDCK cells, their titers were comparable to each other and to WT viruses at later time points. All introduced substitutions were stable except for B/YAM-D342S and B/YAM-A395V which reverted to WT sequences after three passages. Our data suggest that inferring susceptibility to NAIs based on sequence information alone should be cautioned. The impact of NA substitution on NAI resistance, viral growth, and enzymatic properties is viral context dependent and should be empirically determined.

Citation: Tewawong N, Marathe BM, Poovorawan Y, Vongpunsawad S, Webby RJ, Govorkova EA (2018) Neuraminidase inhibitor susceptibility and neuraminidase enzyme kinetics of human influenza A and B viruses circulating in Thailand in 2010–2015. PLoS ONE 13(1): e0190877. https://doi.org/10.1371/journal.pone.0190877

Editor: Stephen Mark Tompkins, University of Georgia, UNITED STATES

Received: June 27, 2017; Accepted: December 21, 2017; Published: January 11, 2018

Copyright: © 2018 Tewawong et al. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Data Availability: All relevant data are within the paper.

Funding: This work was supported by the following funding sources: The National Institute of Allergy and Infectious Diseases, National Institutes of Health, Centers of Excellence for Influenza Research and Surveillance (CEIRS) contract no. HHSN272201400006C to Richard J. Webby, the American Lebanese Syrian Associated Charities (ALSAC), The Research Chair Grant from the National Science and Technology Development Agency (P-15-50004) to Yong Poovorawan, and The Center of Excellence in Clinical Virology of Chulalongkorn University (GCE 59-009-30-005) to Yong Poovorawan. Nipaporn Tewawong received the Overseas Research Experience Scholarship for Graduate Students of Chulalongkorn University. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

Competing interests: The NAIs oseltamivir carboxylate (oseltamivir) and zanamivir were provided by Hoffmann-La Roche, Ltd. (Basel, Switzerland). The NAI peramivir was provided by BioCryst Pharmaceuticals (Birmingham, AL). There are no further patents, products in development or marketed products to declare. This does not alter our adherence to all the PLOS ONE policies on sharing data and materials, as detailed online in the guide for authors.

Introduction

Influenza A and B viruses are important human respiratory pathogens that cause annual epidemics worldwide. Anti-influenza prophylaxis and treatment with antiviral drugs are used to prevent and control influenza virus infections, particularly when vaccines are ineffective or unavailable [1]. The Centers for Diseases Control and Prevention (CDC) has reported high levels of resistance (>99%) to adamantanes among circulating seasonal influenza A(H3N2) and pandemic A(H1N1)pdm09 viruses [2]. Therefore, existing options for the prophylaxis and treatment of influenza virus infection are limited to a single class of antiviral drug, neuraminidase inhibitors (NAIs). Three NAIs, namely oral oseltamivir, inhaled zanamivir, and intravenous peramivir, are approved by the United States Food and Drug Administration and are recommended for the prophylaxis and treatment of patients infected with influenza A or B viruses [2].

The influenza neuraminidase (NA) is a tetrameric type II integral membrane protein with sialidase activity that is responsible for releasing newly produced viral particles from virus-infected cells [3, 4]. Based on their sequences, the NA genes of influenza viruses are classified as group 1 (N1, N4, N5, and N8), group 2 (N2, N3, N6, N7, N9) and influenza B NA [5]. In influenza A and B viruses, the NA active site is formed by highly conserved framework (E119, R156, W178, S179, D/N198, I222, E227, H274, E277, N294, and E425 [in N2 numbering]) and catalytic (R118, D151, R152, R224, E276, R292, R371, and Y406) residues [6–8]. NA amino acid substitutions located within or in close proximity to the NA active site can result in reduced inhibition of influenza viruses by NAIs and may affect the NA enzymatic properties, replication efficiency, transmissibility, and fitness of the virus in vitro and in vivo [9–12]. The various NA-subtype specific substitutions arise as a result of selection by different NAIs, and can be detected with different frequencies in clinical samples or in surveillance studies [12]. Although substitutions have been reported at novel residues in NAs, the effect of these substitutions on the NAI susceptibility of viruses with different genetic backgrounds is largely undetermined. Substitutions at residue 222 (T/V/M/L) conferred reduced susceptibility to NAIs and were found in seasonal A(H1N1), A(H1N1)pdm09, and highly pathogenic influenza A(H5N1) viruses. I222T/V NA substitutions were reported to cause reduced susceptibility of A(H5N1) viruses to NAIs, with 60- to 105-fold higher IC₅₀s to oseltamivir when compared to the wild-type NAs [13]. Antiviral surveillance studies identified novel NA substitutions (S331R in influenza A(H3N2) viruses; D342S and A395E in influenza B viruses) that were associated with reduced inhibition by oseltamivir and peramivir (as indicated by higher IC₅₀ values for these compounds) [14–17]. These substitutions were located outside the NA active site [6, 15]. A recent study demonstrated that an influenza A(H1N1)pdm09 variant containing double NA substitution at residues I427T/Q313R outside the NA active site had decreased NAI susceptibility, with altered NA properties and viral fitness [18].

Previously, we reported substitutions at residues 222 and 331 in the NA of influenza A(H3N2) viruses and at residues 342 and 395 in that of influenza B viruses circulating in Thailand [19]. However, the effect of these NA substitutions on the susceptibility to NAIs, the enzymatic properties, and the fitness of the viruses were not determined. Here, we applied reverse genetics and generated recombinant influenza A and B viruses possessing either wild-type (WT) NA or an NA with a single I222V, S331G, or S331R substitution [in influenza A(H3N2) viruses] or a single S342S, A395T, A395V, or A395S substitution [in influenza B viruses].We then used these recombinant viruses to study the properties (activity, enzyme kinetic, thermostability) of their NAs, their susceptibility to NAIs, their replication kinetics, and the genetic stability of the NA substitutions during passages in MDCK cells.

Materials and methods

Clinical samples, influenza viruses, and cells

The novel NA substitutions were identified in influenza A(H3N2) and B viruses in polymerase chain reaction (PCR)-positive respiratory samples from patients in Thailand (Table 1) [19]. Substitution-encoding NA gene sequences were amplified from these samples, which were obtained from the Center of Excellence in Clinical Virology at Chulalongkorn University in Thailand as part of the influenza surveillance program. The study protocol was approved by the Institutional Review Board (IRB) of the Faculty of Medicine at Chulalongkorn University (IRB No. 581/58). The study was conducted according to the ethical principles regarding human experimentation set out in the Declaration of Helsinki, and the IRB waived the need for consent because the samples were de-identified and anonymous.

Download:

Table 1. Novel NA substitutions in influenza A(H3N2) and B PCR-positive samples from Thailand used in the study.

https://doi.org/10.1371/journal.pone.0190877.t001

Influenza B/Brisbane/60/2008 (B/BR/60/08) virus was obtained from the repository at St. Jude Children’s Research Hospital. Madin-Darby canine kidney (MDCK) cells (ATCC, Manassas, VA) were maintained in Eagle’s Minimum Essential Medium supplemented with 5% fetal bovine serum and a mixture of antibiotics and antimycotics (100 U of penicillin, 0.1 mg of streptomycin, and 0.25 μg of amphotericin B/mL). Human embryonic kidney 293T cells (ATCC, Manassas, VA) were maintained in Opti-MEM reduced-serum medium with GlutaMAX supplement at a final concentration of 2 mM (Life Technologies, Gaithersburg, MD) and no antibiotics.

Cloning of NA into pHW2000 and pAD3000 plasmids

Influenza viral RNA was extracted using a RNeasy Kit (Qiagen, CA). The full-length NA genes (numbering is based on an alignment of NAs from the following reference strains: A/Perth/16/2009 (H3N2) and B/Yamanashi/166/1998 [20]) of influenza A(H3N2) and B viruses were amplified by one-step RT-PCR with primers previously described for the NA segments of influenza A [21] and B [22] viruses. PCR products were gel-purified (QIAquick Gel Extraction Kit, Qiagen) and then digested with BsaI [21] or BsmBI [22] restriction enzymes (New England Biolabs, Boston, MA). The plasmid vectors were digested with BsmBI, and the NA segments were ligated with T4 DNA ligase (New England Biolabs, Boston, MA) into pHW2000 (for influenza A NAs) or pAD3000 (for influenza B NAs).

Plasmids were transformed into One Shot chemically competent Escherichia coli cells (Invitrogen, Carlsbad, CA), and positive clones were inoculated into Terrific Broth medium containing ampicillin. The positive clones were purified using HiSpeed Plasmid Maxi Kits (Qiagen, CA), and the plasmid DNA concentrations were determined by both UV spectrophotometry at 260 nm and analysis on agarose gels. The constructed plasmids were sequenced to ensure their identity with the field strains.

Generation of recombinant influenza A and B viruses

Recombinant (7:1) influenza viruses carrying NAs of influenza A(H3N2) or B viruses circulating in Thailand (Table 1) were generated on a homogenous genetic background of A/Puerto Rico/8/1934 (H1N1) (A/PR8) and B/Yamanashi/166/1998 (B/YAM) influenza viruses, respectively. The A/PR8-WT was a 7:1 reassortant with the N2 NA of A/Thailand/CU-B11870/2015 in a background of A/PR8 (Table 1). The eight plasmids were transfected into 293T cells as previously described [22, 23]. The NA gene segment was amplified from the extracted viral RNA of rescued viruses by using one-step RT-PCR. The NAs of recombinant viruses were sequenced by the Hartwell Center for Bioinformatics and Biotechnology at St. Jude Children’s Research Hospital, using BigDye Terminator (version 3) chemistry and synthetic oligonucleotides. Samples were analyzed on Applied Biosystems 3700 DNA analyzers. The NA sequences were analyzed with SeqMan software (DNAStar, Madison, WI). Recombinant viruses were grown in the allantoic cavity of 10-day-old embryonated chicken eggs (Marshall Durbin, Birmingham, AL) for 72 h at 35°C (for influenza A viruses) or 33°C (for influenza B viruses). The virus-containing allantoic fluid was stored at −80°C until use. The 50% tissue culture infectious dose (TCID₅₀) of each recombinant influenza virus was determined in MDCK cells incubated for 72 h at 35°C (for influenza A viruses) or 33°C (for influenza B viruses). The TCID₅₀ values were calculated by the Reed-Muench method [24]. The HA titers were determined by using packed chicken red blood cells diluted to a hematocrit of 0.5%.

NAI susceptibility

The NAIs (oseltamivir carboxylate, zanamivir, and peramivir) were dissolved in sterile distilled water, and aliquots were stored at −20°C until use. A fluorescence-based NA inhibition assay with the fluorogenic substrate 2′-(4-methylumbelliferyl)-α-D-N-acetylneuraminic acid (MUNANA; Sigma-Aldrich, St Louis, MO) was used to determine the 50% inhibitory concentration (IC₅₀) values [25, 26]. Briefly, viruses were standardized to equivalent NA enzyme activity in the linear range of the curve and were mixed with various concentrations of NAI (ranged from 0.05 to 5000 nM in the final reaction mixture) in 96-well flat-bottom black opaque plates (Corning Costar, NY). The virus-NAI mixture was incubated at 37°C for 30 min prior to the addition of MUNANA and then incubated with substrate (100 μM final concentration) at 37°C for 30 min. The reaction was terminated by the addition of the stop solution (0.1 M glycine in 25% ethanol, pH 10.7). Fluorometric determinations were quantified with a Synergy 2 multi-mode microplate reader (BioTek Instruments, Winooski, VT) based on the release of the fluorescent product 4-methylumbelliferone (4-MU) using excitation and emission wavelengths of 360 and 460 nm, respectively. The IC₅₀s of viruses were determined using the curve-fitting model in GraphPad Prism 5 software (GraphPad Software, La Jolla, CA). The phenotypic NAI susceptibility of influenza A and B viruses was evaluated based on the fold change in their IC₅₀ values when compared to those of susceptible viruses from the same NA subtype/lineage, as previously described by the WHO Influenza Antiviral Working Group [14]. The inhibition was categorized as “normal” (a ≤ 10-fold change for influenza A and a ≤ 5-fold change for influenza B viruses); “reduced” (a 10–100-fold change for influenza A and a 5–50-fold change for influenza B viruses); or “highly reduced” (a ≥ 100-fold change for influenza A and a ≥ 50-fold change for influenza B viruses).

NA enzyme activity and thermostability

The NA activity of recombinant viruses was measured by a fluorometric assay with MUNANA substrate as described above [25, 26]. The NA activity was normalized against the amount of infectious virus and presented as the quantity of 4-MU (in μg) formed per 1 log₁₀TCID₅₀ of the virus. The thermostability of the NA was determined by incubating viruses in a gradient thermocycler at 33, 37, 45, or 55°C for 15 or 30 min, then all viruses were brought to room temperature, and NA activity was subsequently measured [25, 26]. The NA activity was determined and expressed as a percentage of the NA activity of the virus at 4°C (unheated). The NA activity of each virus was calculated based on the mean of triplicate assays.

NA enzyme kinetics assay

The enzyme kinetics (V_max and K_m) of the NAs of recombinant influenza A and B viruses with a single NA amino acid substitution were determined as previously described [27]. First, the optimum dilution of recombinant virus to assess NA kinetic properties was determined. Briefly, 2-fold virus dilutions were incubated with the MUNANA substrate (100 μM), and NA activity was measured every 60 s for 60 min to identify virus dilution within a linear range of the curve that converts ≤ 15% of the total amount of MUNANA substrate and signal to noise ration > 10 across most of time course. We then measured the NA enzyme kinetics at pH 6.5 with enzyme buffer and a final concentration of MUNANA substrate ranging from 0.98 to 1000 μM. The reaction was monitored at 37°C in a total volume of 150 μL, and the fluorescence signal was detected every 60 s for 60 min using excitation and emission wavelengths of 360 and 460 nm, respectively. The MUNANA substrate affinity (K_m) and velocity of catalysis (V_max) values were calculated by fitting appropriate Michaelis-Menten equations to the data by using nonlinear regression in GraphPad Prism 5 software.

Replication kinetics

Multi-step growth curves were determined for each recombinant influenza virus in MDCK cells. Confluent cell monolayers were infected with recombinant virus at a multiplicity of infection (MOI) of 1 or 0.001 TCID₅₀/cell. The supernatant was collected at 6, 12, and 24 h (for an MOI of 1 TCID₅₀/cell) and at 24, 48, and 72 h (for an MOI of 0.001 TCID₅₀/cell) after virus inoculation and stored at −70°C until use. Virus titers were determined by TCID₅₀ assays in MDCK cells.

Statistical analysis

The NA activity, IC₅₀ values, enzyme kinetic parameters (K_m and V_max), and virus titers were compared by two-tailed Student’s t-tests. The results were considered significantly different if the P-value was less than 0.05.

Results

NAI susceptibility profiles

We used NA inhibition assays to determine the NAI susceptibility profiles of 7:1 recombinant influenza A and B viruses carrying single NA amino acid substitutions (Table 2). When compared to the IC₅₀ value of the A/PR8-WT virus, the fold changes in the IC₅₀ values of recombinant influenza A viruses were > 10-fold. These results demonstrated that A/PR8 viruses carrying NA from A(H3N2) virus with single I222V, S331R, or S331G NA substitutions were susceptible to NAIs. For the recombinant B/YAM viruses, the fold changes in the IC₅₀ values were > 5-fold when compared to the IC₅₀ of the B/BR/60/08 virus. These results revealed that B/YAM viruses carrying NAs from currently circulating influenza B viruses with single D342S, A395T, A395V, or A395D NA substitutions were susceptible to NAIs.

Download:

Table 2. NAI susceptibility profiles for recombinant influenza A and B viruses carrying a single NA substitution.

https://doi.org/10.1371/journal.pone.0190877.t002

NA enzyme activity

We investigated the effect of NA amino acid substitutions on the NA activity of 7:1 recombinant influenza A and B viruses by using a modified fluorescence-based assay. The NA enzyme sialidase activity was standardized according to the amount of infectious virus (per 1 log₁₀TCID₅₀) and expressed as the quantity of 4-MU (in μg) (Table 3). The NA substitutions at residue 331 (S331G and S331R) significantly decreased the NA activity of recombinant A/PR8 viruses as compared to that of A/PR8-WT NA (P < 0.001 and P < 0.01, respectively), whereas the I222V NA substitution slightly increased the NA activity (Table 3). In contrast, the B/YAM-D342S and B/YAM-A395T viruses had significantly higher NA activity when compared to the reference B/BR/60/08 virus (P < 0.01). The A395D substitution decreased the NA activity of recombinant B/YAM virus, whereas the A395V NA substitution increased the NA activity relative to that of the B/BR/60/08 virus (Table 3). Thus, the S331G substitution had the greatest impact on the NA activity of recombinant A/PR8 viruses, followed by the S331R substitution, and the D342S and A395T substitutions had the greatest effect on the NA activity of recombinant B/YAM viruses.

Download:

Table 3. NA activity and NA enzyme kinetics of recombinant influenza A and B viruses.

https://doi.org/10.1371/journal.pone.0190877.t003

NA enzyme kinetics

To investigate the effect of NA amino acid substitutions on NA enzymatic kinetics, we measured the K_m and V_max of NAs from recombinant influenza A and B viruses by using the fluorogenic MUNANA substrate (Table 3). The K_m of A/PR8 virus NAs carrying S331G and S331R NA substitutions was significantly increased relative to that of WT NA (P < 0.01), whereas the D342S and A395T NA substitutions decreased the K_m of recombinant B/YAM viruses (P < 0.01 and P < 0.05, respectively). The S331G and S331R NA substitutions increased the V_max of recombinant influenza A virus NAs (P < 0.001 and P < 0.01, respectively) (Table 3).

In contrast, the NAs of B/YAM viruses carrying D342S or A395T NA substitutions had a reduced V_max (P < 0.05). The higher V_max of the influenza A virus NA may facilitate the release and spread of A/PR8-S331G and A/PR8-S331R viruses, but the higher K_m indicates that the NA has a low affinity for its substrate. These results suggest that the NA substitutions contribute to the reduction in NA enzymatic activity.

NA thermostability

NA amino acid substitutions can contribute to NA protein stability [11]. Therefore, we determined the thermostability of mutant NAs by measuring the NA activity of the recombinant viruses after 15 and 30 min of incubation at different temperatures. For recombinant influenza A viruses, the NA activity of the A/PR8-I222V virus was stable at 33°C to 55°C, whereas the A/PR8-S331G and A/PR8-S331R viruses showed lower activity at 55°C (Fig 1A and 1B). The NA activity of recombinant B/YAM viruses carrying T/V/D changes at residue 395 and the B/BR/60/08 virus was undetectable after incubation at 55°C. In contrast, virus carrying the D342S NA substitution possessed high NA activity that was thermostable (Fig 1C and 1D).

Download:

Fig 1. The NA thermostability of the recombinant influenza A and B viruses carrying a single NA substitution.

Influenza A/PR8 (A, B) and B/YAM (C, D) viruses were incubated for 15 or 30 min at the indicated temperatures. Residual NA enzyme activity was assayed and is presented as a percentage of the NA activity at 4°C (unheated). The bars represent the mean of the relative NA activity ± SD for different temperatures from three experiments. *P < 0.05.

https://doi.org/10.1371/journal.pone.0190877.g001

Replication kinetics

To evaluate the fitness in vitro of recombinant influenza A and B viruses carrying NA amino acid substitutions, we studied their replication capacity in MDCK cells. At 6 and 12 h post-infection (hpi), the growth of A/PR8-I222V virus was similar to that of A/PR8-WT, but the A/PR8-S331G and A/PR8-S331R virus yields were significantly lower (P < 0.05) (Fig 2A). At 48 hpi, the yields of all recombinant influenza A viruses were comparable (range, 6.8–7.5 log₁₀TCID₅₀/mL) (Fig 2B). At 6 and 12 hpi, the recombinant influenza B virus yields were significantly lower than that of B/BR/60/08 virus (P < 0.05) (Fig 2C). At 48 hpi, all influenza B viruses replicated to significantly higher virus titers in MDCK cells when compared to B/BR/60/08 virus (P < 0.05) (Fig 2D). At 72 hpi, the viral titers of the recombinant influenza B viruses were 4.2 and 5.2 log₁₀TCID₅₀/mL. These results demonstrated that the NA substitutions S331G and S331R (on an A/PR8 background) and D342S, A395T, A395V, and A395D (on a B/YAM background) reduced the enzyme activity and thermostability of the NA. Although replication ability of recombinant influenza A and B viruses was heterogeneous at early time points, they showed at least equivalent yields as A/PR8-WT and B/BR/60/08 viruses at later time points. However, using B/BR/60/08 instead of the recombinant B/YAM virus with the wild-type NA is a caveat of this comparison.

Download:

Fig 2. Replication kinetics in MDCK cells of recombinant influenza A and B viruses carrying a single NA amino acid substitution.

MDCK cells were infected with recombinant influenza A and B viruses at an MOI of 1 (A, C) or 0.001 (B, D). Virus titers were determined by TCID₅₀ assays in MDCK cells after incubation for 72 h at 35°C (for influenza A viruses) or 33°C (for influenza B viruses). Each data point represents the mean virus titer (log₁₀TCID₅₀/mL) ± the SD from three independent experiments. *P < 0.05.

https://doi.org/10.1371/journal.pone.0190877.g002

NA genetic stability

To determine whether NA substitutions introduced into the A/PR8 and B/YAM genetic backgrounds could be stably maintained in vitro, the NA genes were amplified from viruses before and after three passages in MDCK cells, and the NA sequences were determined. The I222V, S331G, and S331R NA substitutions were genetically stable in NA proteins on the genetic background of the A/PR8 virus. A diverse pattern was observed for influenza B viruses. The A395T and A395D substitutions were genetically stable and were maintained unchanged during three passages, whereas the D342S and A395V substitutions were unstable and the NAs reverted to WT after three passages (Table 4). These findings indicate that genetically unstable D342S and A395V NA substitutions are unlikely to emerge at a high frequency in influenza B viruses.

Download:

Table 4. Genetic stability of NA substitutions among recombinant influenza A and B viruses after three subsequent passages in MDCK cells.

https://doi.org/10.1371/journal.pone.0190877.t004

Discussion

In this study, we investigated the effect of novel NA amino acid substitutions on the NAI susceptibility, NA enzymatic properties, and replication capacity of influenza viruses in vitro. We generated recombinant (7:1) influenza A and B viruses containing the NA glycoprotein from viruses currently circulating in Thailand on the homogeneous genetic background of A/PR8 and B/YAM viruses for the recombinant influenza A and B viruses, respectively. The conserved I222 framework residue in the NA of influenza virus provides support to the catalytic residues [7]. In our study, the A/PR8-I222V virus was susceptible to NAIs in a phenotypic NA inhibition assay and possessed slightly increased NA enzymatic activity. It was previously reported that an influenza A(H3N2) virus with a single I222V NA amino acid substitution was susceptible to oseltamivir and possessed slightly higher NA enzymatic activity as compared to WT virus [28]. Our data revealed that recombinant A/PR8-I222V virus has only a minor effect on the NA enzymatic properties and virus replication efficiency in MDCK cells. However, the I222V NA substitution has a compensatory effect on the influenza A(H3N2) virus carrying E119V, and the presence of these two substitutions resulted in partially improved viral fitness in cell culture and resistance to oseltamivir [29].

Regarding the S331G/R, D342S, and A395T/D/V NA amino acid substitutions, these are found outside the NA active site, and viruses with these substitutions showed normal inhibition by NAIs. The S331G and S331R substitutions affected the kinetic properties of the NA enzyme, changing its binding affinity (K_m) for MUNANA substrate. The V_max of the A/PR8-S331G and A/PR8-S331R virus NAs was nearly double that of the A/PR8-WT NA, demonstrating the compensatory effect as reflected in the lower replication capacity of viruses carrying S331G and S331R substitutions when compared to viruses with WT or I222V NAs. The significant decrease in NA activity and the increased K_m value demonstrated that S331G and S331R NA substitutions are deleterious to NA functions. The NA activity of the A/PR8-S331G and A/PR8-S331R viruses was decreased, and their viral titers in MDCK cells were lower than those of the WT virus at 6 and 12 hpi. The A/PR8-S331G and A/PR8-S331R viruses were characterized by a loss of NA activity at higher temperature (55°C), whereas PR8-WT and A/PR8-I222V viruses did not lose their NA activity. These data indicate that the viral replication capacity in vitro is dependent on the NA activity and the thermostability of the viruses [11, 30]. The B/YAM-D342S, B/YAM-A395T, and B/YAM-A395V viruses showed increased NA activity, whereas their K_m and V_max values decreased. These data suggest that there is an inverse relationship between NA activity and K_m and V_max values and that these amino acid substitutions are beneficial to NA functions. Moreover, B/YAM-D342S, B/YAM-A395T, and B/YAM-A395V viruses gave significantly higher viral yields at 48 hpi in MDCK cells, as compared to B/BR/60/08 virus. At higher temperature (55°C), the NA activity of recombinant influenza A viruses carrying NA substitutions was more stable than that of influenza B viruses. The A395V and D342S NA substitutions on the B/YAM background were unstable, and the NAs reverted to WT after three passages in vitro.

There were a few limitations in this study. As we could not generate a recombinant B/YAM virus with WT NA protein by using reverse genetics, we used the B/BR/60/08 virus, which is genetically similar to viruses circulating in Thailand, and compared the NA enzymatic properties and viral replication efficiency in vitro. Therefore, our results require validation using the B/YAM-WT NA virus. NAs from influenza A(H3N2) PCR-positive samples with I222V, S331G, and S331R NA substitutions were generated in the A/PR8 (H1N1) backbone. The replication efficiency of these viruses in MDCK cells may differ from that of natural isolates because of the effect of the HA-NA balance [31]. Although we used a validated and standardized method to determine influenza NA enzymatic properties using a whole virus preparation as a source of enzyme [27], this approach has limitations. Standardization of NA content based on TCID₅₀ does not account for defective/non-infectious virions in the virus preparations, which may be enzymatically active. NA content can be reliably standardized in purified NA proteins; however, protein production on this scale, and when evaluating numerous viruses/proteins, is not readily achievable.

In conclusion, the recombinant influenza A and B viruses containing different NA substitutions located outside the NA active site exhibited normal inhibition by NAIs but differed in their NA enzymatic properties and their replication capacity in vitro. Continuous influenza antiviral surveillance is important for the identification of molecular markers of antiviral resistance and the characterization of NA enzyme functions and viral fitness.

Acknowledgments

We thank Keith A. Laycock, PhD, ELS, for excellent editing of the manuscript and the staff of the Hartwell Center for Bioinformatics and Biotechnology for their help with the Sanger sequencing. The NAIs oseltamivir carboxylate (oseltamivir) and zanamivir were provided by Hoffmann-La Roche, Ltd. (Basel, Switzerland). The NAI peramivir was provided by BioCryst Pharmaceuticals (Birmingham, AL).

References

1. Fiore AE, Fry A, Shay D, Gubareva L, Bresee JS, Uyeki TM; Centers for Disease Control and Prevention (CDC). Antiviral agents for the treatment and chemoprophylaxis of influenza: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep. 2011; 60(1):1–24. pmid:21248682
- View Article
- PubMed/NCBI
- Google Scholar
2. Centers for Diseases Control and Prevention. Influenza antiviral medications: summary for clinicians. [Cited 2017 March 29]. Available from: https://www.cdc.gov/flu/pdf/professionals/antivirals/antiviral-summary-clinician-updated.pdf.
3. Palese P, Tobita K, Ueda M, Compans RW. Characterization of temperature sensitive influenza virus mutants defective in neuraminidase. Virology 1974; 61(2):397–410. pmid:4472498
- View Article
- PubMed/NCBI
- Google Scholar
4. Li W, Shi W, Qiao H, Ho SY, Luo A, Zhang Y, et al. Positive selection on hemagglutinin and neuraminidase genes of H1N1 influenza viruses. Virol J. 2011; 8:183. pmid:21507270
- View Article
- PubMed/NCBI
- Google Scholar
5. Gamblin SJ, Skehel JJ. Influenza hemagglutinin and neuraminidase membrane glycoproteins. J Biol Chem. 2010; 285(37):28403–28409. pmid:20538598
- View Article
- PubMed/NCBI
- Google Scholar
6. Colman PM, Varghese JN, Laver WG. Structure of the catalytic and antigenic sites in influenza virus neuraminidase. Nature 1983; 303(5912):41–44. pmid:6188957
- View Article
- PubMed/NCBI
- Google Scholar
7. Burmeister WP, Ruigrok RW, Cusack S. The 2.2 Å resolution crystal structure of influenza B neuraminidase and its complex with sialic acid. EMBO J. 1992; 11(1):49–56. pmid:1740114
- View Article
- PubMed/NCBI
- Google Scholar
8. Colman PM, Hoyne PA, Lawrence MC. Sequence and structure alignment of paramyxovirus hemagglutinin-neuraminidase with influenza virus neuraminidase. J Virol. 1993; 67(6):2972–2980. pmid:8497041
- View Article
- PubMed/NCBI
- Google Scholar
9. Yen HL, Hoffmann E, Taylor G, Scholtissek C, Monto AS, Webster RG, et al. Importance of neuraminidase active-site residues to the neuraminidase inhibitor resistance of influenza viruses. J Virol. 2006; 80(17):8787–8795. pmid:16912325
- View Article
- PubMed/NCBI
- Google Scholar
10. Nguyen HT, Fry AM, Gubareva LV. Neuraminidase inhibitor resistance in influenza viruses and laboratory testing methods. Antivir Ther. 2012; 17(1 Pt B):159–173. pmid:22311680
- View Article
- PubMed/NCBI
- Google Scholar
11. Burnham AJ, Baranovich T, Govorkova EA. Neuraminidase inhibitors for influenza B virus infection: efficacy and resistance. Antiviral Res. 2013; 100(2):520–534. pmid:24013000
- View Article
- PubMed/NCBI
- Google Scholar
12. Govorkova EA. Consequences of resistance: in vitro fitness, in vivo infectivity, and transmissibility of oseltamivir-resistant influenza A viruses. Influenza Other Respir Viruses. 2013;7 Suppl 1:50–57. pmid:23279897
- View Article
- PubMed/NCBI
- Google Scholar
13. McKimm-Breschkin JL, Barrett S, Pudjiatmoko, Azhar M, Wong FY, Selleck P, et al. I222 neuraminidase mutations further reduce oseltamivir susceptibility of Indonesian clade 2.1 highly pathogenic avian influenza A(H5N1) viruses. PLoS One. 2013; 8(6):e66105. pmid:23776615
- View Article
- PubMed/NCBI
- Google Scholar
14. WHO. Weekly epidemiological record (WER). 2012; 87(39):369–380. Available from: http://www.who.int/wer/2012/wer8739/en/.
15. Leang SK, Kwok S, Sullivan SG, Maurer-Stroh S, Kelso A, Barr IG, et al. Peramivir and laninamivir susceptibility of circulating influenza A and B viruses. Influenza Other Respir Viruses. 2014; 8(2):135–139. pmid:24734292
- View Article
- PubMed/NCBI
- Google Scholar
16. Hurt AC, Besselaar TG, Daniels RS, Ermetal B, Fry A, Gubareva L, et al. Global update on the susceptibility of human influenza viruses to neuraminidase inhibitors, 2014–2015. Antiviral Res. 2016; 132:178–185. pmid:27265623
- View Article
- PubMed/NCBI
- Google Scholar
17. Leang SK, Deng YM, Shaw R, Caldwell N, Iannello P, Komadina N, et al. Influenza antiviral resistance in the Asia-Pacific region during 2011. Antiviral Res. 2013; 97(2):206–210. pmid:23274624
- View Article
- PubMed/NCBI
- Google Scholar
18. Tu V, Abed Y, Barbeau X, Carbonneau J, Fage C, Lagüe P, Boivin G. The I427T neuraminidase (NA) substitution, located outside the NA active site of an influenza A(H1N1)pdm09 variant with reduced susceptibility to NA inhibitors, alters NA properties and impairs viral fitness. Antiviral Res. 2017; 137:6–1313. pmid:27838351
- View Article
- PubMed/NCBI
- Google Scholar
19. Tewawong N, Vichiwattana P, Korkong S, Klinfueng S, Suntronwong N, Thongmee T, et al. Evolution of the neuraminidase gene of seasonal influenza A and B viruses in Thailand between 2010 and 2015. PLoS One. 2017; 12(4):e0175655. pmid:28410396
- View Article
- PubMed/NCBI
- Google Scholar
20. The WHO GISRS Antiviral Susceptibility Expert Working Group (AVWG). Summary of neuraminidase amino acid substitutions associated with reduced inhibition by neuraminidase inhibitors (NAI). Last updated 21 October 2016. Available from: http://www.who.int/influenza/gisrs_laboratory/antiviral_susceptibility/avwg2014_nai_substitution_table.pdf?ua=1.
21. Hoffmann E, Stech J, Guan Y, Webster RG, Perez DR. Universal primer set for the full-length amplification of all influenza A viruses. Arch Virol. 2001; 146(12):2275–2289. pmid:11811679
- View Article
- PubMed/NCBI
- Google Scholar
22. Hoffmann E, Mahmood K, Yang CF, Webster RG, Greenberg HB, Kemble G. Rescue of influenza B virus from eight plasmids. Proc Natl Acad Sci U S A. 2002; 99(17):11411–11416. pmid:12172012
- View Article
- PubMed/NCBI
- Google Scholar
23. Hoffmann E, Neumann G, Kawaoka Y, Hobom G, Webster RG. A DNA transfection system for generation of influenza A virus from eight plasmids. Proc Natl Acad Sci U S A. 2000; 97(11):6108–6113. pmid:10801978
- View Article
- PubMed/NCBI
- Google Scholar
24. Reed LJ, Muench H. A simple method for estimating fifty percent endpoints. Am J Hyg. 1938; 27:493–497.
- View Article
- Google Scholar
25. Gubareva LV, Webster RG, Hayden FG. Detection of influenza virus resistance to neuraminidase inhibitors by an enzyme inhibition assay. Antiviral Res. 2002; 53(1):47–61. pmid:11684315
- View Article
- PubMed/NCBI
- Google Scholar
26. Potier M, Mameli L, Bélisle M, Dallaire L, Melançon SB. Fluorometric assay of neuraminidase with a sodium (4-methylumbelliferyl-alpha-D-N-acetylneuraminate) substrate. Anal Biochem. 1979; 94(2):287–296. pmid:464297
- View Article
- PubMed/NCBI
- Google Scholar
27. Marathe BM, Lévêque V, Klumpp K, Webster RG, Govorkova EA. Determination of neuraminidase kinetic constants using whole influenza virus preparations and correction for spectroscopic interference by a fluorogenic substrate. PLoS One 2013; 8:e71401. pmid:23977037
- View Article
- PubMed/NCBI
- Google Scholar
28. Baz M, Abed Y, McDonald J, Boivin G. Characterization of multidrug-resistant influenza A/H3N2 viruses shed during 1 year by an immunocompromised child. Clin Infect Dis. 2006; 43(12):1555–15561. pmid:17109288
- View Article
- PubMed/NCBI
- Google Scholar
29. Simon P, Holder BP, Bouhy X, Abed Y, Beauchemin CA, Boivin G. The I222V neuraminidase mutation has a compensatory role in replication of an oseltamivir-resistant influenza virus A/H3N2 E119V mutant. J Clin Microbiol. 2011;49(2):715–717. pmid:21106781
- View Article
- PubMed/NCBI
- Google Scholar
30. Burnham AJ, Baranovich T, Marathe BM, Armstrong J, Webster RG, Govorkova EA. Fitness costs for Influenza B viruses carrying neuraminidase inhibitor-resistant substitutions: underscoring the importance of E119A and H274Y. Antimicrob Agents Chemother. 2014; 58(5):2718–2730. pmid:24566185
- View Article
- PubMed/NCBI
- Google Scholar
31. Little K, Leang SK, Butler J, Baas C, Harrower B, Mosse J, et al. Zanamivir-resistant influenza viruses with Q136K or Q136R neuraminidase residue mutations can arise during MDCK cell culture creating challenges for antiviral susceptibility monitoring. Euro Surveill. 2015; 20(45). pmid:26608955
- View Article
- PubMed/NCBI
- Google Scholar

[ref1] 1. Fiore AE, Fry A, Shay D, Gubareva L, Bresee JS, Uyeki TM; Centers for Disease Control and Prevention (CDC). Antiviral agents for the treatment and chemoprophylaxis of influenza: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep. 2011; 60(1):1–24. pmid:21248682
View Article
PubMed/NCBI
Google Scholar

[2] View Article

[3] PubMed/NCBI

[4] Google Scholar

[ref2] 2. Centers for Diseases Control and Prevention. Influenza antiviral medications: summary for clinicians. [Cited 2017 March 29]. Available from: https://www.cdc.gov/flu/pdf/professionals/antivirals/antiviral-summary-clinician-updated.pdf.

[ref3] 3. Palese P, Tobita K, Ueda M, Compans RW. Characterization of temperature sensitive influenza virus mutants defective in neuraminidase. Virology 1974; 61(2):397–410. pmid:4472498
View Article
PubMed/NCBI
Google Scholar

[7] View Article

[8] PubMed/NCBI

[9] Google Scholar

[ref4] 4. Li W, Shi W, Qiao H, Ho SY, Luo A, Zhang Y, et al. Positive selection on hemagglutinin and neuraminidase genes of H1N1 influenza viruses. Virol J. 2011; 8:183. pmid:21507270
View Article
PubMed/NCBI
Google Scholar

[11] View Article

[12] PubMed/NCBI

[13] Google Scholar

[ref5] 5. Gamblin SJ, Skehel JJ. Influenza hemagglutinin and neuraminidase membrane glycoproteins. J Biol Chem. 2010; 285(37):28403–28409. pmid:20538598
View Article
PubMed/NCBI
Google Scholar

[15] View Article

[16] PubMed/NCBI

[17] Google Scholar

[ref6] 6. Colman PM, Varghese JN, Laver WG. Structure of the catalytic and antigenic sites in influenza virus neuraminidase. Nature 1983; 303(5912):41–44. pmid:6188957
View Article
PubMed/NCBI
Google Scholar

[19] View Article

[20] PubMed/NCBI

[21] Google Scholar

[ref7] 7. Burmeister WP, Ruigrok RW, Cusack S. The 2.2 Å resolution crystal structure of influenza B neuraminidase and its complex with sialic acid. EMBO J. 1992; 11(1):49–56. pmid:1740114
View Article
PubMed/NCBI
Google Scholar

[23] View Article

[24] PubMed/NCBI

[25] Google Scholar

[ref8] 8. Colman PM, Hoyne PA, Lawrence MC. Sequence and structure alignment of paramyxovirus hemagglutinin-neuraminidase with influenza virus neuraminidase. J Virol. 1993; 67(6):2972–2980. pmid:8497041
View Article
PubMed/NCBI
Google Scholar

[27] View Article

[28] PubMed/NCBI

[29] Google Scholar

[ref9] 9. Yen HL, Hoffmann E, Taylor G, Scholtissek C, Monto AS, Webster RG, et al. Importance of neuraminidase active-site residues to the neuraminidase inhibitor resistance of influenza viruses. J Virol. 2006; 80(17):8787–8795. pmid:16912325
View Article
PubMed/NCBI
Google Scholar

[31] View Article

[32] PubMed/NCBI

[33] Google Scholar

[ref10] 10. Nguyen HT, Fry AM, Gubareva LV. Neuraminidase inhibitor resistance in influenza viruses and laboratory testing methods. Antivir Ther. 2012; 17(1 Pt B):159–173. pmid:22311680
View Article
PubMed/NCBI
Google Scholar

[35] View Article

[36] PubMed/NCBI

[37] Google Scholar

[ref11] 11. Burnham AJ, Baranovich T, Govorkova EA. Neuraminidase inhibitors for influenza B virus infection: efficacy and resistance. Antiviral Res. 2013; 100(2):520–534. pmid:24013000
View Article
PubMed/NCBI
Google Scholar

[39] View Article

[40] PubMed/NCBI

[41] Google Scholar

[ref12] 12. Govorkova EA. Consequences of resistance: in vitro fitness, in vivo infectivity, and transmissibility of oseltamivir-resistant influenza A viruses. Influenza Other Respir Viruses. 2013;7 Suppl 1:50–57. pmid:23279897
View Article
PubMed/NCBI
Google Scholar

[43] View Article

[44] PubMed/NCBI

[45] Google Scholar

[ref13] 13. McKimm-Breschkin JL, Barrett S, Pudjiatmoko, Azhar M, Wong FY, Selleck P, et al. I222 neuraminidase mutations further reduce oseltamivir susceptibility of Indonesian clade 2.1 highly pathogenic avian influenza A(H5N1) viruses. PLoS One. 2013; 8(6):e66105. pmid:23776615
View Article
PubMed/NCBI
Google Scholar

[47] View Article

[48] PubMed/NCBI

[49] Google Scholar

[ref14] 14. WHO. Weekly epidemiological record (WER). 2012; 87(39):369–380. Available from: http://www.who.int/wer/2012/wer8739/en/.

[ref15] 15. Leang SK, Kwok S, Sullivan SG, Maurer-Stroh S, Kelso A, Barr IG, et al. Peramivir and laninamivir susceptibility of circulating influenza A and B viruses. Influenza Other Respir Viruses. 2014; 8(2):135–139. pmid:24734292
View Article
PubMed/NCBI
Google Scholar

[52] View Article

[53] PubMed/NCBI

[54] Google Scholar

[ref16] 16. Hurt AC, Besselaar TG, Daniels RS, Ermetal B, Fry A, Gubareva L, et al. Global update on the susceptibility of human influenza viruses to neuraminidase inhibitors, 2014–2015. Antiviral Res. 2016; 132:178–185. pmid:27265623
View Article
PubMed/NCBI
Google Scholar

[56] View Article

[57] PubMed/NCBI

[58] Google Scholar

[ref17] 17. Leang SK, Deng YM, Shaw R, Caldwell N, Iannello P, Komadina N, et al. Influenza antiviral resistance in the Asia-Pacific region during 2011. Antiviral Res. 2013; 97(2):206–210. pmid:23274624
View Article
PubMed/NCBI
Google Scholar

[60] View Article

[61] PubMed/NCBI

[62] Google Scholar

[ref18] 18. Tu V, Abed Y, Barbeau X, Carbonneau J, Fage C, Lagüe P, Boivin G. The I427T neuraminidase (NA) substitution, located outside the NA active site of an influenza A(H1N1)pdm09 variant with reduced susceptibility to NA inhibitors, alters NA properties and impairs viral fitness. Antiviral Res. 2017; 137:6–1313. pmid:27838351
View Article
PubMed/NCBI
Google Scholar

[64] View Article

[65] PubMed/NCBI

[66] Google Scholar

[ref19] 19. Tewawong N, Vichiwattana P, Korkong S, Klinfueng S, Suntronwong N, Thongmee T, et al. Evolution of the neuraminidase gene of seasonal influenza A and B viruses in Thailand between 2010 and 2015. PLoS One. 2017; 12(4):e0175655. pmid:28410396
View Article
PubMed/NCBI
Google Scholar

[68] View Article

[69] PubMed/NCBI

[70] Google Scholar

[ref20] 20. The WHO GISRS Antiviral Susceptibility Expert Working Group (AVWG). Summary of neuraminidase amino acid substitutions associated with reduced inhibition by neuraminidase inhibitors (NAI). Last updated 21 October 2016. Available from: http://www.who.int/influenza/gisrs_laboratory/antiviral_susceptibility/avwg2014_nai_substitution_table.pdf?ua=1.

[ref21] 21. Hoffmann E, Stech J, Guan Y, Webster RG, Perez DR. Universal primer set for the full-length amplification of all influenza A viruses. Arch Virol. 2001; 146(12):2275–2289. pmid:11811679
View Article
PubMed/NCBI
Google Scholar

[73] View Article

[74] PubMed/NCBI

[75] Google Scholar

[ref22] 22. Hoffmann E, Mahmood K, Yang CF, Webster RG, Greenberg HB, Kemble G. Rescue of influenza B virus from eight plasmids. Proc Natl Acad Sci U S A. 2002; 99(17):11411–11416. pmid:12172012
View Article
PubMed/NCBI
Google Scholar

[77] View Article

[78] PubMed/NCBI

[79] Google Scholar

[ref23] 23. Hoffmann E, Neumann G, Kawaoka Y, Hobom G, Webster RG. A DNA transfection system for generation of influenza A virus from eight plasmids. Proc Natl Acad Sci U S A. 2000; 97(11):6108–6113. pmid:10801978
View Article
PubMed/NCBI
Google Scholar

[81] View Article

[82] PubMed/NCBI

[83] Google Scholar

[ref24] 24. Reed LJ, Muench H. A simple method for estimating fifty percent endpoints. Am J Hyg. 1938; 27:493–497.
View Article
Google Scholar

[85] View Article

[86] Google Scholar

[ref25] 25. Gubareva LV, Webster RG, Hayden FG. Detection of influenza virus resistance to neuraminidase inhibitors by an enzyme inhibition assay. Antiviral Res. 2002; 53(1):47–61. pmid:11684315
View Article
PubMed/NCBI
Google Scholar

[88] View Article

[89] PubMed/NCBI

[90] Google Scholar

[ref26] 26. Potier M, Mameli L, Bélisle M, Dallaire L, Melançon SB. Fluorometric assay of neuraminidase with a sodium (4-methylumbelliferyl-alpha-D-N-acetylneuraminate) substrate. Anal Biochem. 1979; 94(2):287–296. pmid:464297
View Article
PubMed/NCBI
Google Scholar

[92] View Article

[93] PubMed/NCBI

[94] Google Scholar

[ref27] 27. Marathe BM, Lévêque V, Klumpp K, Webster RG, Govorkova EA. Determination of neuraminidase kinetic constants using whole influenza virus preparations and correction for spectroscopic interference by a fluorogenic substrate. PLoS One 2013; 8:e71401. pmid:23977037
View Article
PubMed/NCBI
Google Scholar

[96] View Article

[97] PubMed/NCBI

[98] Google Scholar

[ref28] 28. Baz M, Abed Y, McDonald J, Boivin G. Characterization of multidrug-resistant influenza A/H3N2 viruses shed during 1 year by an immunocompromised child. Clin Infect Dis. 2006; 43(12):1555–15561. pmid:17109288
View Article
PubMed/NCBI
Google Scholar

[100] View Article

[101] PubMed/NCBI

[102] Google Scholar

[ref29] 29. Simon P, Holder BP, Bouhy X, Abed Y, Beauchemin CA, Boivin G. The I222V neuraminidase mutation has a compensatory role in replication of an oseltamivir-resistant influenza virus A/H3N2 E119V mutant. J Clin Microbiol. 2011;49(2):715–717. pmid:21106781
View Article
PubMed/NCBI
Google Scholar

[104] View Article

[105] PubMed/NCBI

[106] Google Scholar

[ref30] 30. Burnham AJ, Baranovich T, Marathe BM, Armstrong J, Webster RG, Govorkova EA. Fitness costs for Influenza B viruses carrying neuraminidase inhibitor-resistant substitutions: underscoring the importance of E119A and H274Y. Antimicrob Agents Chemother. 2014; 58(5):2718–2730. pmid:24566185
View Article
PubMed/NCBI
Google Scholar

[108] View Article

[109] PubMed/NCBI

[110] Google Scholar

[ref31] 31. Little K, Leang SK, Butler J, Baas C, Harrower B, Mosse J, et al. Zanamivir-resistant influenza viruses with Q136K or Q136R neuraminidase residue mutations can arise during MDCK cell culture creating challenges for antiviral susceptibility monitoring. Euro Surveill. 2015; 20(45). pmid:26608955
View Article
PubMed/NCBI
Google Scholar

[112] View Article

[113] PubMed/NCBI

[114] Google Scholar

Figures

Abstract

Introduction

Materials and methods

Clinical samples, influenza viruses, and cells

Cloning of NA into pHW2000 and pAD3000 plasmids

Generation of recombinant influenza A and B viruses

NAI susceptibility

NA enzyme activity and thermostability

NA enzyme kinetics assay

Replication kinetics

Statistical analysis

Results

NAI susceptibility profiles

NA enzyme activity

NA enzyme kinetics

NA thermostability

Replication kinetics

NA genetic stability

Discussion

Acknowledgments

References